Nestle Looks to Develop New Products to Serve Users of Weight-Loss Drugs
The company is using artificial intelligence and nutritional science to target side effects like muscle loss as GLP-1 drug use expands.
- On Monday, Nestle announced it is using artificial intelligence to develop products for around 16 million Americans taking GLP-1 weight-loss drugs, converting the medication trend into a business opportunity.
- Rapid weight loss from drugs like Novo Nordisk's Wegovy and Ozempic often causes muscle loss and facial fat reduction known as "Ozempic face," which Nestle believes its specialized products can help address.
- Chief Technology Officer Stefan Palzer said the firm uses AI to process research and navigate a database of roughly 120,000 recipes, with products like Boost Advanced Nutrition Shake containing 35 grams of protein.
- Amanda Avery, associate professor in nutrition and dietetics at the University of Nottingham, cautioned that consumers are susceptible to marketing and whole foods offer similar nutrients at lower costs than specialized products.
- Nestle uses AI-driven simulations to predict consumer responses to new products before market launch, with Palzer stating, "Increasingly AI will get into this field" as the company identifies emerging trends.
15 Articles
15 Articles
Nestlé: How it wants to make a profit from Ozempic – The new market created by weight loss drugs
Nestlé seeks to transform the advancement of GLP-1 drugs for weight loss from a threat into a business opportunity, using artificial intelligence and nutrition science to develop products aimed at millions of consumers who use medicines such as Ozempic and Wegovy. The rapid adoption of the drugs manufactured by Novo Nordisk and Eli Lilly fuelled investors' concerns that medicines that reduce appetite can permanently reduce demand for industriali…
Nestle Leverages AI to Transform GLP-1 Drug Side Effects into Business Opportunities
Nestle is utilizing AI to turn the threat of GLP-1 weight-loss drugs into a business opportunity by developing nutritional products for users of medicines like Ozempic. The company addresses side effects such as muscle loss through targeted products and extensive clinical research, while also focusing on consumer trends.
Based on the information so far, he wants to create mostly protein-rich products, but the question is how much of a need there is for these instead of whole foods.
The drugs from Novo Nordisk and Eli Lilly curb appetite, which leads to rapid weight loss. However, the weight loss syringe is not intended to reduce Nestlé's sales. The food giant takes first steps.
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
